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Background and PurposezzSerial nerve conduction studies (NCSs) are recommended for 
differentiating axonal and demyelinating Guillain-Barré syndrome (GBS), but this approach 
is not suitable for early diagnoses. This study was designed to identify possible NCS parame-
ters for differentiating GBS subtypes.
MethodszzWe retrospectively reviewed the medical records of 70 patients with GBS who un-
derwent NCS within 10 days of symptom onset. Patients with axonal GBS and acute inflamma-
tory demyelinating polyneuropathy (AIDP) were selected based on clinical characteristics and 
serial NCSs. An antiganglioside antibody study was used to increase the diagnostic certainty.
ResultszzThe amplitudes of median and ulnar nerve sensory nerve action potentials (SNAPs) 
were significantly smaller in the AIDP group than in the axonal-GBS group. Classification 
and regression-tree analysis revealed that the distal ulnar sensory nerve SNAP amplitude was 
the best predictor of axonal GBS.
ConclusionszzEarly upper extremity sensory NCS findings are helpful in differentiating ax-
onal-GBS patients with antiganglioside antibodies from AIDP patients.
Key Wordszz Guillain-Barré syndrome, acute inflammatory demyelinating polyneuropathy, 
early diagnosis, electrodiagnosis, neural conduction.
Early Electrodiagnostic Features of Upper Extremity Sensory 
Nerves Can Differentiate Axonal Guillain-Barré Syndrome 
from Acute Inflammatory Demyelinating Polyneuropathy
INTRODUCTION
Guillain-Barré syndrome (GBS) is an immune-mediated inflammatory neuropathy with 
various subtypes, including acute inflammatory demyelinating polyneuropathy (AIDP), 
acute axonal motor neuropathy, acute motor and sensory axonal neuropathy, pharyngeal-
cervical-brachial variant, and Miller-Fisher syndrome. GBS and its subtypes can generally 
be diagnosed clinically, but differentiating these subtypes—especially between AIDP and 
axonal GBS—can be challenging.
Acute axonal polyneuropathy is caused by molecular mimicry of human gangliosides by 
Campylobacter jejuni lipo-oligosaccharides.1 In axonal GBS, autoantibodies bind to gangli-
osides at the nodes of Ranvier, activating the complement system and disrupting sodium-
channel clusters and axoglial junctions. However, AIDP directly attacks the myelin sheath, 
resulting in segmental demyelination and remyelination, although the exact pathophysiol-
ogy of AIDP has not been established. Differences in pathophysiology should foster efforts 
to differentiate the GBS subtypes accurately, aiding future clinical research.
Electrodiagnostic study is the gold standard for differentiating between axonal and my-
elin lesions in early-stage acute polyneuropathy. However, current electrodiagnostic criteria 
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have some limitations in diagnosing axonal GBS.2-4 The ax-
onal type of GBS is pathophysiologically characterized not 
only by axonal degeneration, but also by reversible conduction 
failure. An inability to distinguish between demyelinating 
conduction block, reversible conduction failure, and length-
dependent compound muscle action potential (CMAP) am-
plitude reduction may result in patients with axonal GBS be-
ing incorrectly classified as having AIDP.1,2
One recent study suggested that serial nerve conduction 
studies (NCSs) with thorough follow-ups are required to cor-
rectly differentiate GBS subtypes.2 Antiganglioside antibody 
tests will facilitate a correct diagnosis. However, these ap-
proaches are not suitable for early diagnosis due to the long 
period required to perform repeated NCSs. In this study we 
assessed the diagnostic value of various NCS parameters for 
differentiating early-stage axonal GBS from early-stage AIDP.
METHODS
Subjects
We retrospectively reviewed the Korean Inflammatory Neu-
ropathy Consortium registry database, which holds data 
gathered from eight nationwide institutions in South Korea. 
Data obtained between January 2012 and December 2014 
were reviewed using the following inclusion criteria: 1) di-
agnosis of GBS according to the current diagnostic criteria 
and clinically confirmed as axonal GBS or AIDP through se-
rial NCSs with a follow-up period of more than 6 months,3,5,6 
2) first NCS performed within 10 days of symptom onset, 
and 3) availability of antiganglioside antibody results. We ex-
cluded patients with underlying diseases that can cause neu-
ropathy, such as diabetes mellitus, malignancy, and chronic 
alcohol consumption. Patients with a previous history of a pe-
ripheral nerve disease or radiculopathy other than GBS were 
also excluded. A precise classification was ensured by assay-
ing antiganglioside antibodies. Patients who displayed clini-
cal characteristics of axonal GBS and seropositivity for gan-
glioside antibodies were included in the final analysis. The 
AIDP group included patients with seronegativity for anti-
ganglioside antibodies. Antibodies to gangliosides were tested 
using an enzyme-linked immunosorbent assay, as described 
elsewhere,1,7 with the serum considered to be seropositive for 
antiganglioside antibodies when the titer was ≥1:400. The 
Institutional Review Boards at all of the participating insti-
tutions approved this study: Korea University Anam Hospi-
tal, Yonsei University Severance Hospital, Dong-A University 
Hospital, Chonnam National University Hospital, Inje Uni-
versity Haeundae Paik Hospital, Hallym University Kang-
dong Sacred Heart Hospital, Kangbuk Samsung Hospital, and 
Konkuk University Medical Center. Informed consent was 
obtained from all subjects in the registry database.
Electrodiagnostic studies
All of the institutions followed the standard NCS protocol to 
exclude possible confounding factors.8 Motor NCSs of the 
median, ulnar, peroneal, and tibial nerves were recorded at 
the abductor pollicis brevis, abductor digiti minimi, extensor 
digitorum brevis, and abductor hallucis, respectively. A stim-
ulus duration of 0.1 ms, a sensitivity setting of 2 mV, a sweep 
speed of 2 ms/division, and filtering from 5 Hz to 5 kHz were 
applied in all measurements. Sensory NCSs were performed 
on median and ulnar nerves using the orthodromic method, 
and on the sural nerve using the antidromic method. A sen-
sitivity setting of 10 μV, a sweep speed of 1 ms/division, and 
filtering from 20 Hz to 3 kHz were used. F-waves were mea-
sured from the investigated motor nerves.
NCS parameters
For the motor nerves, we obtained the latency, amplitude, 
and duration of CMAPs by stimulating at both the proximal 
sites (elbow for the median and ulnar nerves, popliteal fossa 
for the tibial nerve, and fibular head for the peroneal nerve) 
and distal sites (wrist for the median and ulnar nerves, and 
ankle for the tibial and peroneal nerves). The conduction 
velocity was calculated for the segment between the proxi-
mal and distal stimulation sites. The CMAP amplitude was 
measured from baseline to the negative peak. The CMAP 
duration was measured from the onset of a negative deflec-
tion from the baseline to when the last negative wave re-
turned to the baseline. We also obtained F-wave latencies 
from these motor nerves. Conduction block was considered 
to be present in a specific nerve if the proximal-to-distal am-
plitude ratio was less than 0.5.3 For the median and ulnar sen-
sory nerves, we measured the sensory nerve action poten-
tial (SNAP) amplitude at both the proximal and distal sites, 
in addition to measuring the distal latency. We also measured 
the conduction velocity at the distal regions (from wrist to fin-
ger for the median and ulnar nerves) and proximal regions 
(from elbow to wrist for the median and ulnar nerves). The 
SNAP amplitude was measured as the peak-to-peak ampli-
tude. The conduction velocity and SNAP amplitude were mea-
sured for the sural nerve.
We compared each NCS parameter between the axonal-
GBS and AIDP groups. Since results were available from only 
one side of a specific nerve in some patients, we chose to use 
the NCS data of the more-affected side when both sides had 
been measured.
Statistical analysis
Continuous variables were compared between groups using 
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Student’s t-tests or Mann-Whitney U tests depending on the 
variable distribution. Categorical variables were compared 
using chi-square tests or Fisher’s exact tests. We assessed the 
optimal sensitivity and specificity of each nerve in discrimi-
nating axonal GBS from AIDP using receiver operating char-
acteristic (ROC) curves, with cutoff values being determined. 
The classification and regression tree (CART) algorithm was 
also used to discriminate axonal-GBS patients from AIDP 
patients. The sensitivity was defined as the proportion of pa-
tients who were classified as axonal GBS according to the tree 
model among all axonal-GBS patients, and the specificity 
was the proportion of patients who were classified as AIDP 
according to the tree model among all AIDP patients. The 
analysis was performed using all NCS data and then repeated 
using only motor NCS data due to the predominant involve-
ment of motor neurons in axonal GBS. Probability values 
of p<0.05 were considered statistically significant. Statistical 
analyses were performed using SPSS (version 20.0, SPSS Inc., 
Chicago, IL, USA) and R version 3.0.3 (R foundation for Sta-
tistical Computing Vienna, Austria) software.
RESULTS
Subjects
Of 118 patients with GBS spectrum disorders, 70 patients 
with classic GBS were selected after excluding 31 patients 
with Miller-Fisher syndrome and 17 patients with the pha-
ryngeal-cervical-brachial variant. After reviewing the anti-
ganglioside antibody, only 27 seronegative AIDP patients 
and 31 seropositive patients classified as having axonal GBS 
were included. Among these patients, we finally analyzed 19 
AIDP patients (9 men; age 57.4±15.0 years, mean±SD) and 
25 axonal-GBS patients (12 men, age 58.2±11.2 years) who 
underwent the first NCSs within 10 days of symptom onset.
The antibody profile in the axonal-GBS group was as follows: 
immunoglobulin (Ig) G type GM1 antibody was found in 18 
patients, GD1a in 4, GD1b in 6, GD3 in 1, GT1a in 2, GT1b in 
1, GQ1b in 4, and IgM type GM1 in 3 patients.
NCS parameters
The NCS results are presented in Table 1. The median distal 
CMAP latencies for all motor nerves were significantly de-
layed in the AIDP group than in the axonal-GBS group. Com-
Table 1. Comparison of nerve conduction study parameters between 
axonal GBS and acute inflammatory demyelinating polyneuropathy
Axonal GBS AIDP p
Median motor
DL 4.0 (3.7, 4.5) 5.7 (4.9, 8.1) <0.001*
CV 51.2 (45.4, 54.0) 43.8 (33.7, 49.5) 0.003*
Dist. Amp. 3.9 (2.7, 5.6) 3.5 (1.6, 4.5) 0.359
Prox. Amp. 3.5 (1.7, 5.0) 3.0 (1.2, 4.3) 0.303
Dist. Dur. 6.2 (5.6, 7.1) 8.4 (6.8, 13.0) 0.008*
Prox. Dur. 6.4 (5.9, 7.5) 9.8 (7.5, 12.0) 0.003*
F Lat. 32.5 (27.4, NP) 38.1 (32.1, NP) 0.225
Ulnar motor
DL 2.9 (2.7, 3.2) 3.8 (3.2, 4.9) 0.010*
CV 53.8 (50.9, 57.3) 48.0 (45.3, 53.8) 0.040*
Dist. Amp. 5.4 (2.9, 7.6) 5.6 (2.0, 8.3) 1.000
Prox. Amp. 3.4 (2.6, 6.5) 3.8 (1.9, 7.0) 0.969
Dist. Dur. 6.3 (6.0, 7.8) 8.1 (7.5, 9.5) 0.014*
Prox. Dur. 6.9 (6.2, 7.5) 8.3 (7.5, 9.5) 0.024*
F Lat. NP (30.6, NP) 34.2 (30.0, NP) 0.192
Tibial motor
DL 5.1 (4.2, 6.3) 6.8 (5.5, 7.9) 0.007*
CV 42.2 (40.0, 45.3) 38.6 (33.5, 41.5) 0.006*
Dist. Amp. 5.3 (2.8, 9.8) 3.8 (1.1, 6.4) 0.205
Prox. Amp. 4.1 (2.0, 8.0) 1.9 (0.8, 3.7) 0.058
Dist. Dur. 5.8 (5.5, 6.7) 7.7 (6.3, 14.9) 0.054
Prox. Dur. 6.6 (6.4, 7.5) 10.5 (9.1, 27.3) 0.001*
F Lat. 54.6 (50.4, NP) 67.8 (54.4, NP) 0.148
Peroneal motor
DL 4.6 (4.3, 6.3) 10.6 (6.4, 13.3) <0.001*
CV 42.0 (38.2, 44.0) 34.7 (10.7, 38.6) <0.001*
Dist. Amp. 1.7 (1.1, 2.5) 1.5 (0.3, 2.1) 0.118
Prox. Amp. 1.4 (0.8, 2.5) 1.0 (0.1, 1.4) 0.083
Dist. Dur. 6.3 (5.7, 8.5) 10.8 (7.6, 19.7) 0.010*
Prox. Dur. 6.8 (6.0, 9.3) 13.7 (9.6, 46.2) <0.001*
F Lat. NP (NP, NP) NP (63.4, NP) 0.287
Median sensory
CV 43.0 (40.6, 47.0) 37.9 (NP, 40.6) <0.001*
Prox. CV 52.6 (50.1, 54.0) 48.5 (38.0, 52.1) 0.053
Dist. Amp. 18.3 (12.8, 25.1) 5.3 (NP, 7.8) <0.001*
Prox. Amp. 30.0 (21.0, 37.0) 16.2 (6.8, 30.6) 0.024*
Ulnar sensory
CV 42.8 (39.9, 46.5) 37.5 (NP, 40.4) <0.001*
Prox. CV 54.2 (51.0, 57.9) 51.4 (46.5, 56.1) 0.135
Dist. Amp. 14.0 (11.0, 17.4) 1.8 (NP, 7.0) <0.001*
Prox. Amp. 23.3 (19.8, 37.3) 13.9 (6.8, 22.9) 0.002*
Table 1. Comparison of nerve conduction study parameters between 
axonal GBS and acute inflammatory demyelinating polyneuropathy 
(continued)
Axonal GBS AIDP p
Sural sensory
CV 37.0 (35.9, 42.8) 35.0 (32.2, 38.5) 0.077
Amp. 13.5 (10.9, 21.7) 15.6 (7.1, 17.9) 0.121
The data in parentheses represent interquartile ranges.
*p<0.05.
AIDP: acute inflammatory demyelinating polyneuropathy, Amp.: am-
plitude, AXONAL GBS: acute axonal Guillain-Barré syndrome, CV: con-
duction velocity, Dist.: distal, DL: distal latency, Dur.: duration, F Lat.: F-
wave latency, NP: not provoked, Prox.: proximal.
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pared to the axonal-GBS group, the median conduction ve-
locities in the AIDP group were significantly reduced in the 
median sensory nerve, the ulnar sensory nerve, and all motor 
nerves. None of the CMAP amplitudes differed between the 
groups. Furthermore, the proportion of patients with conduc-
tion blocks did not differ between the axonal-GBS (eight pa-
tients, 32%) and AIDP (seven patients, 37%) groups. SNAP 
amplitudes in the AIDP group were significantly decreased 
in the median and ulnar nerves.
Using parameters that differed significantly between the 
two groups, we calculated the sensitivity and the specificity 
with a specific cutoff point (Table 2). Distal SNAP amplitudes 
of the median and ulnar nerves were the strongest discrimi-
nators between the two groups. Considering only motor 
NCS parameters, the distal latency of the peroneal CMAP 
was the best predictor of axonal GBS.
Multivariate analyses
According to the CART analysis, the distal ulnar SNAP am-
plitude was selected as the best predictor for discriminating 
axonal GBS from AIDP (Fig. 1A). The tree started from a root 
node (node 0) containing both axonal-GBS and AIDP patients. 
This node was then split based on the distal ulnar SNAP am-
plitude. Subjects with ulnar sensory nerve SNAP amplitudes 
of ≤7.5 mV were grouped into node 1, which comprised 15 
AIDP patients (88%) and 2 axonal-GBS patients (12%). The 
remaining subjects were grouped into node 2, comprising of 
4 AIDP patients (15%) and 23 axonal-GBS patients (85%). The 
sensitivity and specificity of this model for predicting axonal 
GBS were 92% and 79%, respectively. 
When we considered only the motor nerves, the distal la-
tency in the peroneal motor nerve and the duration in the 
proximal tibial motor nerve were the best predictors of axo-
nal GBS (Fig. 1B). Node 0 was split based on the CMAP dis-
tal latency obtained from the peroneal nerve, creating node 1 
(≤7.935 ms) and node 2 (>7.935 ms). The subjects in node 1 
were split into nodes 3 and 4 based on the proximal CMAP 
duration obtained from the tibial nerve using a cutoff value 
of 7.125 ms. Patients with a distal latency in the peroneal 
motor nerve of longer than 7.935 ms were more likely to be 
diagnosed as AIDP. Among the patients with a distal latency 
in the peroneal motor nerve of shorter than 7.935 ms, all of 
them whose proximal duration in the tibial nerve was less 
than 7.125 ms had axonal GBS. The overall sensitivity and 
specificity of this model were 96% and 63%, respectively.
DISCUSSION
We investigated early NCS findings in GBS patients in order 
to discriminate patients with axonal GBS and seropositivity 
Table 2. Sensitivity and specificity of nerve conduction study parameters determined by receiver operating characteristics curves
Cutoff point for Axonal GBS Sensitivity Specificity AUC (95% CI)
Median (S) Dist. Amp. ≥12.50 0.944 0.783 0.921 (0.837–1.000)
Ulnar (S) Dist. Amp. ≥7.50 0.789 0.920 0.903 (0.814–0.993)
Median (S) CV ≥41.85 0.947 0.720 0.856 (0.746–0.966)
Peroneal (M) DL ≤7.93 0.632 0.952 0.855 (0.736–0.974)
Median (M) DL ≤4.85 0.789 0.840 0.825 (0.695–0.955)
Ulnar (S) CV ≥39.45 0.632 0.875 0.817 (0.685–0.949)
Peroneal (M) CV ≥40.15 0.842 0.667 0.813 (0.681–0.944)
Peroneal (M) Prox. Dur. ≤9.07 0.833 0.739 0.803 (0.666–0.940)
Tibial (M) Prox. Dur. ≤7.46 0.882 0.739 0.803 (0.653–0.953)
Ulnar (S) Prox. Amp. ≥13.95 0.526 1.000 0.773 (0.628–0.917)
Median (M) Prox. Dur. ≤7.23 0.882 0.652 0.779 (0.627–0.930)
Median (M) CV ≥50.85 0.842 0.640 0.762 (0.612–0.912)
Tibial (M) CV ≥39.65 0.632 0.840 0.742 (0.589–0.895)
Tibial (M) DL ≤5.55 0.750 0.680 0.753 (0.590–0.915)
Median (M) Dist. Dur. ≤7.20 0.706 0.783 0.749 (0.588–0.910)
Ulnar (M) DL ≤3.20 0.737 0.792 0.730 (0.566–0.895)
Peroneal (M) Dist. Dur. ≤7.18 0.833 0.652 0.736 (0.570–0.901)
Ulnar (M) Dist. Dur. ≤6.79 0.882 0.591 0.731 (0.562–0.900)
Median (S) Prox. Amp. ≥17.55 0.526 0.880 0.701 (0.540–0.862)
Ulnar (M) Prox. Dur. ≤8.03 0.706 0.857 0.716 (0.530–0.901)
Ulnar (M) CV ≥52.65 0.684 0.708 0.684 (0.519–0.850)
Amp.: amplitude, AUC: area under the curve, AXONAL GBS: acute axonal Guillain-Barré syndrome, CI: confidence interval, CV: conduction velocity, 
Dist.: distal, DL: distal latency, Dur.: duration, M: motor, Prox.: proximal, S: sensory.
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for antiganglioside antibodies from patients with AIDP. Early 
NCS parameters that could be used to differentiate these two 
groups were the distal latency, conduction velocity, and the 
amplitude of various motor and sensory nerve potentials, es-
pecially upper limb distal SNAP amplitudes and lower limb 
CMAP latencies or durations.
Axonal GBS is associated with Campylobacter jejuni infec-
tion,9,10 which mimics gangliosides in humans, subsequently 
resulting in the production of autoantibodies to the ganglio-
sides.11 Since gangliosides stabilize paranodal junctions and 
ion-channel clusters in myelinated nerve fibers,12 the antigan-
glioside antibodies can cause axonal GBS.13 The pathogenesis 
of GBS associated with antiganglioside antibodies appears to 
involve complement activation, which could be utilized as a 
target for therapy.1,14 Since prompt identification of this sub-
type of GBS leads to early treatment, it is important to differ-
entiate this subtype from AIDP, which is not usually associated 
with antiganglioside antibodies. However, the current diag-
nostic criteria for GBS are not particularly useful for differenti-
ating axonal GBS from AIDP in the early stage since some pa-
tients with axonal GBS have transient conduction blocks.2,15,16
The present results are similar to previous suggestions that 
patients with antiganglioside antibodies have shorter distal 
latencies and faster conduction velocities in motor nerves, as 
well as larger amplitudes and faster conduction velocities in 
sensory nerves.17 There are many reports of a single electro-
physiological study being considered inadequate for classify-
ing disease subtypes.2,15,17 Although it was suggested recently 
that a single electrophysiological study may be used to diag-
nose GBS subtypes correctly,18 information about antigangli-
oside antibodies was not reported. Overall, our results sup-
port the usefulness of early NCS findings in addition to 
seropositivity for antiganglioside antibodies in the diagnosis 
of axonal GBS.
In GBS, abnormalities cannot be detected in electrodiag-
nostic studies until 2 weeks after symptom onset,19 which 
might hinder early treatment. This has prompted many at-
tempts to diagnose AIDP earlier using electrodiagnostic stud-
ies.20-22 A recent study proposed new diagnostic criteria for 



























































Fig. 1. Classification and regression tree (CART) diagram for discriminating acute axonal Guillain-Barré syndrome (GBS) from acute inflammatory 
demyelinating polyneuropathy (AIDP) using a set of independent variables. A: CART diagram involving a set of independent variables related to 
both motor and sensory nerves. According to this model, patients in nodes 1 and 2 were classified as AIDP and axonal-GBS patients, respectively. 
B: CART diagram involving variables for motor nerves only. According to this model, patients in nodes 3 and 4 were classified as axonal GBS, and 
those in node 2 were classified as AIDP patients. PerMDL: distal latency in peroneal motor nerve, TibMPDur: duration in proximal tibial motor 
nerve, UlnSDAm: distal amplitude in ulnar sensory nerve.
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81% and a specificity of 67%.21 That study found that the 
most common findings of early AIDP were abnormalities in 
the H-reflexes (97%), motor conduction velocity (78%), and 
distal latency in motor nerves (78%).21 Another important 
early finding was a sural sparing pattern.23 In line with these 
previous results, our study also found decreased conduction 
velocities and prolonged distal latencies of motor nerves in 
AIDP patients. Furthermore, the sural sensory nerves were 
not affected in either axonal-GBS or AIDP patients. We used 
ROC curves to identify which NCS parameters are the most 
useful in differentiating AIDP from axonal GBS, which re-
vealed that the areas under the ROC curves were larger for 
the SNAP amplitude and conduction velocity in both medi-
an and ulnar nerves, and for the CMAP distal latency and du-
ration in the peroneal nerve. Consistent with the literature,16,24 
conduction blocks could not be used to differentiate axonal 
GBS from AIDP. A particularly notable finding was that the 
results for the median and ulnar sensory nerves were the most 
powerful for differentiating axonal GBS from AIDP. This is 
consistent with a previous study showing that axonal GBS 
with antiganglioside antibodies rarely involves sensory nerves, 
and that the presence of abnormal sensory conduction is 
more likely to be indicative of AIDP.25 CART analysis showed 
that distal ulnar SNAP amplitude was the most powerful 
discriminating parameter. When we performed the analysis 
using only motor parameters, the distal peroneal CMAP la-
tency and the proximal tibial CMAP duration were the most 
promising for discriminating between axonal GBS and AIDP. 
However, these two motor NCS parameters require careful 
interpretation due to the high likelihood of technical error.
Our study was limited by the smallness of the sample, 
which hindered the ability to draw definitive conclusions. 
However, we classified GBS based on the antibody status as 
well as clinical features and serial NCS findings, which en-
sured subject homogeneity. Further prospective studies in-
volving various subtypes of antiganglioside antibodies should 
be performed to confirm our findings and to develop more 
reliable electrodiagnostic criteria for early-stage axonal GBS.
In conclusion, conduction block is one of the key findings 
used to differentiate demyelinating lesions from axonal le-
sions, but it was found to not be useful in differentiating 
AIDP from axonal GBS. However, we found that the distal 
SNAP amplitude in the median and ulnar nerves was power-
ful in discriminating between axonal GBS and AIDP. Al-
though a single electrodiagnostic study cannot completely 
differentiate axonal GBS from AIDP in early-stage disease, 
careful interpretation of NCS parameters might be helpful in 
their differentiation.
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